Subscribe
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Articles
Axillary Lymph Node Dissection Unnecessary for Some Early-Stage Breast Cancer Patients
TON - Daily
Christin Melton
Data published in the
Journal of the American Medical Association
last week indicate that for 20% of women with early-stage breast cancer, removing malignant lymph nodes from the armpit does not improve survival or prevent recurrence. As expected, women in the phase III trial who underwent complete axillary lymph node dissection (ALND) had higher rates of lymphedema than those who had sentinel lymph node dissection (SLND) alone (
P
<.001). They also had higher rates of wound infection, axillary seromas, and paresthesias (70% vs 25%, respectively;
P
<.001).
The phase III multicenter study, known as the American College of Surgeons Oncology Group Z0011 trial, was conducted at 115 sites from May 1999 to December 2004 to assess whether SLND was noninferior to ALND. In total, 891 women with similar clinical and disease characteristics were randomized to ALND or SLND and followed for a median of 6.3 years with regular physical examinations and annual mammograms.
All women enrolled in the study had stage T1-T2 noninvasive tumors (5 cm or less), with no more than 2 positive sentinel lymph nodes at biopsy, no palpable axillary nodes, and no metastatic spread. Initial treatment consisted of lumpectomy, and 605 underwent whole-breast radiation; women who had received neoadjuvant hormonal therapy or chemotherapy were ineligible. Following surgery, 403 women in the ALND group and 423 in the SLND-only arm received adjuvant systemic therapy, with the types of therapy given fairly well balanced between the study arms. Women in the ALND group had an average of 17 nodes removed compared with 2 in the SLND arm.
At a median of 6.3 years after enrollment, 52 women in the ALND group had died compared with 42 in the SLND group, for an unadjusted hazard ratio of 0.79 (90% confidence interval, 0.56-1.10), which the authors said demonstrated the noninferiority of SLND alone (
P
= .008). The 5-year overall survival (OS) rates were also similar between the groups, at 92.5% in the SLND-only arm and 91.8% in the ALND group. No statistically significant difference in survival rates was observed when stratifying the patients according to estrogen or progesterone receptor status.
Prior to initiating the study, the investigators had anticipated a 5-year OS rate of 80% and planned to end the study once 500 deaths occurred. The surprisingly low death rate led them to close the study early.
In the SLND-only arm, 83.9% of women had no recurrence at 5 years compared with 82.2% of women in the ALND group (
P
= .14). The 5-year rate of local recurrence was 1.6% in the SLND-only arm versus 3.1% in the ALND group, supporting the conclusion that ALND does not prevent recurrence.
The authors concluded that "the only rationale for ALND in these patients would be if the finding of additional nodal metastases would result in changes in systemic therapy." Since current treatment guidelines generally call for the same adjuvant therapy regimen regardless of nodal status, "ALND does not appear to be warranted in this patient population," said the authors.
For women with early-stage breast cancer similar to the women in this study, foregoing ALND offers the potential to improve quality of life significantly. Armando E. Giuliano, MD, chief of surgical oncology at the John Wayne cancer Institute at St. John's Health Center, Santa Monica, California, was lead author of the study. He presented preliminary findings last year at the annual meeting of the American Society of Clinical Oncology and noted then that it might be hard for some physicians to abandon ALND, which has been standard practice for at least a century.
Additional studies will need to determine whether women with more than 2 positive sentinel nodes or matted nodes can safely forego ALND. The complete article is available online at the
Journal of the American Medical Association
.
Related Items
Guidelines on Screening for Breast, Prostate, and Lung Cancers
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
TON - August 2011 VOL 4, NO 5
Supportive Care
,
Palliative Care
,
Conference Correspondent
Having Evidence-Based Discussions on CAM
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Advanced Practice Nurses Forge New Ground in Radiation Oncology Units
By
Christin Melton
Web Exclusives
Conference Correspondent
Changing the Paradigm of Care for Dying Patients
By
Christin Melton
TON - June 2011, Vol 4, No 4
Conference Correspondent
Genotyping: Looking at the Future of Lung Cancer Care
By
Christin Melton
Web Exclusives
Conference Correspondent
Managing Hyperglycemia in Patients Receiving Steroid Treatment
By
Christin Melton
Web Exclusives
Conference Correspondent
A Review of Investigational Drugs at HOPA
By
Christin Melton
Web Exclusives
Drug Updates
Oncology Nurses Best Positioned to Talk to Patients About Lymphedema
By
Christin Melton
Web Exclusives
Conference Correspondent
Preventing Skeletal-Related Events in Patients
By
Christin Melton
Web Exclusives
Conference Correspondent
View the Latest Issue of TON
Read Issue
Home
Issues
Online First
2024
February 2024 - Vol 17 No 1
2023
December 2023 - Vol 16 No 6
October 2023 - Vol 16 No 5
August 2023 - Vol 16 No 4
June 2023 - Vol 16 No 3
April 2023 - Vol 16 No 2
February 2023 - Vol 16 No 1
Issue Archive
Special Issues
Supplements
Guide to New FDA Approvals
Categories
Conference Correspondent
ESMO 2023 - Small Cell Lung Cancer
ONS 2023 - Multiple Myeloma: Wrap-Up
Web Exclusives
OFS Summit
Breast Cancer-OFS Monthly Minutes
Interview with the Innovators
Drug Updates
Media Library
Videos
Rapid Reactions
Audiocasts
Ask the Experts
Master Class Series
Resources
Quick Quiz
CE
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
TON
Print Edition
TON
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
TON
's
Privacy Policy
, and
TON
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION